References

cardiovascular

Кардиоваскулярная терапия и профилактика

Cardiovascular Therapy and Prevention

1728-88002619-0125

«SILICEA-POLIGRAF» LLC

cardiovascular-2109

Research Article

МНЕНИЕ ПО ПРОБЛЕМЕ

OPINION ON A PROBLEM

Тиазидные диуретики: 50 лет истории или взгляд в будущее

Thiazide diuretics: 50 years of history or looking into the future

Фомин

И. В.

Fomin

I. V.

заведующий кафедры внутренних болезней и сестринского дела

fomin-i@yandex.ru

Нижегородская государственная медицинская академия. Нижний НовгородNizhniy Novgorod State Medical Academy. Nizhny Novgorod

2010

20082010

948894

2010

Фомин И.В.

Fomin I.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://cardiovascular.elpub.ru/jour/article/view/2109

Представлена история использования тиазидных диуретиков за последние 50 лет. Рассматривается их влияние на эффективность лечения артериальной гипертонии, сердечно-сосудистую смертность и заболеваемость. Оцениваются их эффекты на гемодинамику и безопасность назначения.

The history of thiazide diuretics’ use during the last 50 years is reviewed. The effects of thiazide diuretics on arterial hypertension treatment effectiveness, cardiovascular mortality and cardiovascular morbidity are discussed. In addition, their hemodynamic effects and safety profile are assessed.

тиазидные диуретикигемодинамические эффектыбезопасность леченияартериальная гипертония

thiazide diureticshemodynamic effectstreatment safetyarterial hypertension

References1

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.

ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.

Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваск тер профил 2008; 7(6), Приложение 2.

Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-31.

Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy. Health Technol Assess 2003; 7 (31).

Moser M, Feig PU. Fifty Years of Thiazide Diuretic Therapy for Hypertension, Arch Intern Med 2009; 169(20): 1851-6.

Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004; 292: 43-4.

Chen JMH, Heran BS, Wright JM. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD007187. DOI: 10.1002/14651858. CD 007187. pub2.

Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.

Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents. JAMA 1958; 166: 137-40.

Moser M, Macaulay AI. Chlorothiazide as an adjunct in the treatment of essential hypertension. Am J Cardiol 1959; 3: 214-9.

Ernst ME, Moser M. Use of Diuretics in Patients with Hypertension. N Engl J Med 2009; 361: 2153-64.

Veterans Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-34.

Wolff FW, Lindeman RD. Effects Morbidity of Treatment on in Hypertension: II. Results in Patients With Diastolic Blood Pressure Averaging 90 Through 114 mm Hg. JAMA, Aug 1970; 213: 1143-52.

Psaty BM, Smith NL, Siscovick DS, et al. Health Outcomes Associated With Antihypertensive Therapies Used as First-Line Agents: A Systematic Review and Meta-analysis. JAMA 1997; 277: 739-45.

Amery A, Birkenhäger WH, Bulpitt CJ, et al. The European Working Party on High blood pressure in the Elderly. Am J Med 1991; 90(Suppl 3A): 1S-64.

Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534-44.

Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009 jul 8;(3): CD001841.

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.

Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669-80.

Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-3.

Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD000028. DOI: 10.1002/14651858. CD000028. pub2.

Messerli FH, Grossman E, Goldbourt U. Are -blockers efficacious as first-line therapy for hypertension in the elderly: a systematic review. JAMA 1998; 279: 1903-7.

Zezulka AV, Gill JS, Beevers DG. The effects of bendroflumethiazide added to nifedipine in patients with hypertension. J Clin Pharmacol 1987; 27: 41-5.

MacGregor GA, Cappuccio FP. Lack of effect of a diuretic added to diltiazem. J Hum Hypertens 1997; 11: 249-50.

Sarwat IC, Harlan MK, Jo Anne MF. Systolic Hypertension in Older Persons. JAMA 2004; 292: 1074-80.

Cushman WC, Materson BJ, Williams DW, Reda DJ. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001; 38: 953-7.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.

Chang JJ, Luchsinger JA, Shea S. Antihypertensive medication class and pulse pressure in the elderly: analysis based on the Third National Health and Nutrition Examination Survey. Am J Med 2003; 115: 536-42.

Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-52.

Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension: Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16(12 pt 1): 1823-9.

Bulpitt CJ, Beckett NS, Fletcher AE, et al. Withdrawal from treatment in the Syst-Eur Trial. J Hypertens 2002; 20: 339-46.

Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation 1959; 20: 1028-36.

Roos JC, Boer P, Koomans HA, et al. Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol 1981; 19: 107-12.

Konstam MA, Neaton JD, Dickstein K, et al. Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-8.

Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.

Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.

Gifford RW Jr, Mattox VR, Orvis AL, et al. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation 1961; 24: 1197-205.

de Carvalho JG, Dunn FG, Lohmöller G, Frohlich ED. Hemodynamic correlates of prolonged thiazide therapy: comparison of responders and nonresponders. Clin Pharmacol Ther 1977; 22: 875-80.

Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978; 95: 611-8.

Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst 2004; 5: 155-60.

Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886-894.

Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982-8.

Curb JD, Pressel SL, Cutrel JA, et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 188-92.

Sica DA, Moser M. Diuretic therapy in cardiovascular disease. In Black HR, Elliott WJ, eds. Hypertension: a companion to Braunwald’s heart disease. Philadelphia: W.B. Saunders, 2007.

Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995; 26: 394-400.

Dussol B, Moussi-Frances J, Morange S, et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005; 20: 349-53.

Grimm RH Jr, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997; 157: 638-48.

Carter BL, Einhorn PT, Brands M, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 2008; 52: 30-6.

Cushman WC, Khatri I, Materson BJ, et al. Treatment of hypertension in the elderly. III. Response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a Department of Veterans Affairs cooperative study. Arch Intern Med 1991; 151: 1954-60.

Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981; 141: 1015-9.

Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401-9.

Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191-201.

Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169: 832-42.

The authors declare that there are no conflicts of interest present.